VISTAGEN THERAPEUTICS, INC. Deferred Revenue, Revenue Recognized
VISTAGEN THERAPEUTICS, INC. (VTGN) reported Deferred Revenue, Revenue Recognized of $0 for the 3-month period ending 2021-06-30, per its 10-Q filed 2021-08-12.
Discontinued › Income Statement › Other Income
us-gaap:DeferredRevenueRevenueRecognized1 · last filed 2021-08-12
- VISTAGEN THERAPEUTICS, INC. deferred revenue, revenue recognized for the quarter ending 2021-06-30 was $0.00.
| Period end | Deferred Revenue, Revenue Recognized 3 month | Deferred Revenue, Revenue Recognized 6 month | Deferred Revenue, Revenue Recognized 9 month |
|---|---|---|---|
| 2021-06-30 | $0.00 10-Q · filed 2021-08-12 | ||
| 2020-12-31 | $5.00M 10-Q · filed 2021-02-11 | ||
| 2020-09-30 | $5.00M 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |